Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Turn Bristol-Myers Squibb into an Income Machine with This Options Play

Turn Bristol-Myers Squibb into an Income Machine with This Options Play

Investors seeking income in the midst of market volatility may find Bristol-Myers Squibb (BMY) an attractive option. With a low Beta of 0.22 and a high dividend yield of 3.90%, BMY provides a solid foundation for generating income. Trading at roughly $6,761 for 100 shares, purchasing the stock would cost $6,761. On the September 18, 2026 expiration date, a call option with a $70 strike price trades at approximately $1.12, generating $112 in premium per contract for covered call sellers.

By selling this call option, investors can earn an income of 1.7% over 30 days, which equates to an annualized return of around 20.5%. Combined with the yearly dividend of $4.12, the total annualized yield rises to 24.40%. Even if the stock price rises above the $70 strike price at expiration, the trader would still achieve a significant return of $351, or 5.3% on the shares plus the initial premium of $112, amounting to a 64.2% annualized return.

However, there is a risk that BMY may decline in value, potentially eroding any profits from selling the call option. While Bristol-Myers Squibb is a leading specialty biopharmaceutical company with a strong oncology portfolio, including blockbuster drugs like Opdivo, it is essential to acknowledge the inherent risks associated with options trading.

As with any investment, thorough research and consultation with a financial advisor are crucial before making any decisions.

Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at finance.yahoo.com →

More in Finance & Markets

More from Thursday 20 August →